Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
Bone Marrow Transplantation|March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMTOlivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.
Blood|July 12, 2015
Disease evolution and outcomes in familial AML with germline CEBPA mutationsKiran Tawana, Jun Wang, Aline Renneville, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Pageof 24